ANIMAL MODELS SHARED RESOURCE The Animal Models (AM) SR has a long and productive history providing experimental assistance to Cancer Center members. The Genetically engineered mouse models (GEMMs), Cell-line Derived Syngeneic or Xenografts (CDX) models and Patient Derived Xenografts (PDX) models are central to LCCC basic and translational research. This is an endeavor that the LCCC and UNC helped to create through the work of the late Oliver Smithies who won the Nobel Prize for his groundbreaking techniques to allow creation of gene modified mouse models. The AM SR has grown dramatically in scope and usage over the last 20 years and is now composed of services for the creation, investigation at multiple levels and imaging of animal models of cancer. These services include: innovative methods for transgenic/knockout allele production and design, generation of PDX models from primary human tumors, allele phenotyping and colony management, animal imaging and tumorigenicity studies in CDXs (both syngeneic immunocompetent and immunocompromised models), PDXs and GEMMs. The AM SR assists Cancer Center members in the planning and execution of carefully designed animal studies. The availability of this SR and its highly skilled personnel eliminates the need for Cancer Center investigators to hire similar individuals within their laboratories and ensures a high level of rigor and reproducibility for their experiments. The three arms of this SR facility; 1) GEMM production, 2) surgery on and experimental testing of syngeneic mouse, CDX and PDX mouse models, 3) translational cancer imaging, benefit from a team of three experienced Facility Directors and well-trained staff. Users of this SR benefit from significant cost reduction and decreased completion times for their studies. The AM SR requests $235,252 from the CCSG to fund this facility in fiscal year 2020; this represents approximately 6% of the total FY19 operating costs for the AM SR which was used by over 100 labs 74% of whom were LCCC members.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016086-45
Application #
10089826
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-06-01
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ma, Shaohua; Paiboonrungruan, Chorlada; Yan, Tiansheng et al. (2018) Targeted therapy of esophageal squamous cell carcinoma: the NRF2 signaling pathway as target. Ann N Y Acad Sci 1434:164-172
Aung, Kyaw L; Fischer, Sandra E; Denroche, Robert E et al. (2018) Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial. Clin Cancer Res 24:1344-1354
Suh, Junghyun L; Watts, Brian; Stuckey, Jacob I et al. (2018) Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry 57:2140-2149
Brock, William J; Beaudoin, James J; Slizgi, Jason R et al. (2018) Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease. Int J Toxicol 37:144-154
Thomas, Nancy E; Edmiston, Sharon N; Tsai, Yihsuan S et al. (2018) Utility of TERT Promoter Mutations for Cutaneous Primary Melanoma Diagnosis. Am J Dermatopathol :
Bensen, Jeannette T; Graff, Mariaelisa; Young, Kristin L et al. (2018) A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Res 20:45
Hall, Marissa G; Marteau, Theresa M; Sunstein, Cass R et al. (2018) Public support for pictorial warnings on cigarette packs: an experimental study of US smokers. J Behav Med 41:398-405
Thorsson, V├ęsteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Wu, Bing; Zhang, Song; Guo, Zengli et al. (2018) RAS P21 Protein Activator 3 (RASA3) Specifically Promotes Pathogenic T Helper 17 Cell Generation by Repressing T-Helper-2-Cell-Biased Programs. Immunity 49:886-898.e5
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10

Showing the most recent 10 out of 1525 publications